Format

Send to

Choose Destination
Nat Commun. 2015 Apr 27;6:6838. doi: 10.1038/ncomms7838.

Manipulation of B-cell responses with histone deacetylase inhibitors.

Author information

1
1] Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia [2] Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia.
2
Leukocyte Signaling Laboratory, Department of Immunology, Monash University, Level 6 Burnet Institute, 89 Commercial Road, Melbourne, Victoria 3004, Australia.
3
1] Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia [2] Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia [3] Department of Medicine, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Victoria 3800, Australia [4] Department of Clinical Haematology, Monash Medical Centre, Clayton, Victoria 3800, Australia.
4
Department of Medicine, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Victoria 3800, Australia.
5
Department of Pathology, Monash Medical Centre, Clayton, Victoria 3800, Australia.
6
The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, Victoria 3052, Australia.

Abstract

Histone deacetylase inhibitors (HDACi) are approved for treating certain haematological malignancies, however, recent evidence also illustrates they are modulators of the immune system. In experimental models, HDACi are particularly potent against malignancies originating from the B-lymphocyte lineage. Here we examine the ability of this class of compounds to modify both protective and autoimmune antibody responses. In vitro, HDACi affect B-cell proliferation, survival and differentiation in an HDAC-class-dependent manner. Strikingly, treatment of lupus-prone Mrl/lpr mice with the HDACi panobinostat significantly reduces autoreactive plasma-cell numbers, autoantibodies and nephritis, while other immune parameters remain largely unaffected. Immunized control mice treated with panobinostat or the clinically approved HDACi vorinostat have significantly impaired primary antibody responses, but these treatments surprisingly spare circulating memory B cells. These studies indicate that panobinostat is a potential therapy for B-cell-driven autoimmune conditions and HDACi do not induce major long-term detrimental effects on B-cell memory.

PMID:
25913720
DOI:
10.1038/ncomms7838
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center